SNSE
Sensei
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Consensus Rating "Strong Buy"
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SNSE
Sensei Biotherapeutics, Inc.
An immuno-oncology company focused on the therapeutics for cancer
Biological Technology
12/01/2017
02/04/2021
NASDAQ Stock Exchange
14
12-31
Common stock
1405 Research Blvd, Suite 125, Rockville, MD 20850
--
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, was incorporated in Delaware on December 1, 2017. The company is an immuno-oncology company focused on the discovery and development of next-generation therapies for cancer patients. Through the TMAb (Tumor Microenvironment Activating Biologics) platform, the Company is developing highly selective therapies designed to selectively disable immunosuppressive signals or activate immune stimulating signals in the tumor microenvironment to release T cells against tumors.
Company Financials
EPS
SNSE has released its 2025 Q1 earnings. EPS was reported at -0.27, versus the expected -0.26, missing expectations. The chart below visualizes how SNSE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
